Proia 7/8
نویسندگان
چکیده
We previously set a three-cell-type coculture system in which neurons and astrocytes synergistically induce brain capillary endothelial cells to form a monolayer with permeability properties resembling those of the physiological blood-brain barrier. Moreover, we recently found that neurons produce fibroblast growth factor-2 and vascular endothelial growth factor and secrete them at least in part by shedding extracellular vesicles. In this study, on the basis of immunofluorescence, scanner electron microscopy and Western blot analyses, we concluded that also astrocytes in culture shed extracellular vesicles that contain the same angiogenic factors, as well as ß1-integrin, a membrane protein that is considered a marker of shedding. Vesicles released by astrocytes are smaller than the ones produced by neurons and have an average size of 150-500 nm.
منابع مشابه
Macular hole secondary to fungal endophthalmitis.
J Pediatr Ophthalmol Strabismus. 1987;24:249254. 7. Fry CL, Leone CR Jr. Safe management of dermolipomas. Arch Ophthalmol. 1994;112:11141116. 8. Ferry AP, Hein HF. Epibulbar osseous choristoma within an epubulbar dermoid. Am J Ophthalmol. 1970;70:764-766. 9. Marback EF, Stout TJ, Rao NA. Osseous choristoma of the conjunctiva simulating extraocular extension of retinoblastoma. Am J Ophthalmol. 2...
متن کاملLymphoid Organs Prion Dissemination between Secondary B Cell-Specific S1PR1 Deficiency Blocks
متن کامل
PPAR ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity
Shenyang Li, Pengfei Wu, Padma Yarlagadda, Nicole M. Vadjunec, Alan D. Proia, Robert A. Harris, and Didier Portilla Division of Nephrology, Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205; Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, Indiana 46202; and...
متن کاملThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequa...
متن کامل